GlassScriptPhysician profile
Raya Hussain
NPI 1093817603
$2,904.73
in general payments reported to CMS, 2019-2025
21 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $204 · 2021: $332 · 2022: $447 · 2023: $368 · 2024: $350 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.83 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $331.24 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $142.91 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $142.00 | 2019-2025 | |
| Exact Sciences Corporation | $131.19 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $96.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $89.04 | 2021-2023 | |
| Novo Nordisk INC | $78.66 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $74.89 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $71.45 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $62.59 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.49 | 2019 | |
| Amgen INC. | $46.05 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $46.05 | 2021-2023 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.79 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $39.89 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.50 | 2021-2023 | Eliquis |
| Nalu Medical, INC. | $20.07 | 2024 | Nalu Neurostimulation System |
| Ardelyx, INC. | $14.26 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raya Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.